JP2024513781A5 - - Google Patents

Info

Publication number
JP2024513781A5
JP2024513781A5 JP2023558897A JP2023558897A JP2024513781A5 JP 2024513781 A5 JP2024513781 A5 JP 2024513781A5 JP 2023558897 A JP2023558897 A JP 2023558897A JP 2023558897 A JP2023558897 A JP 2023558897A JP 2024513781 A5 JP2024513781 A5 JP 2024513781A5
Authority
JP
Japan
Prior art keywords
tumor
clonal
probability
proportion
sequence data
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513781A (ja
Filing date
Publication date
Priority claimed from GBGB2104715.4A external-priority patent/GB202104715D0/en
Application filed filed Critical
Publication of JP2024513781A publication Critical patent/JP2024513781A/ja
Publication of JP2024513781A5 publication Critical patent/JP2024513781A5/ja
Pending legal-status Critical Current

Links

JP2023558897A 2021-04-01 2022-04-01 クローナルなネオ抗原の同定及びその使用 Pending JP2024513781A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2104715.4A GB202104715D0 (en) 2021-04-01 2021-04-01 Identification of clonal neoantigens and uses thereof
GB2104715.4 2021-04-01
PCT/EP2022/058793 WO2022207925A1 (en) 2021-04-01 2022-04-01 Identification of clonal neoantigens and uses thereof

Publications (2)

Publication Number Publication Date
JP2024513781A JP2024513781A (ja) 2024-03-27
JP2024513781A5 true JP2024513781A5 (enExample) 2025-04-28

Family

ID=75883641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558897A Pending JP2024513781A (ja) 2021-04-01 2022-04-01 クローナルなネオ抗原の同定及びその使用

Country Status (10)

Country Link
US (2) US11504398B2 (enExample)
EP (1) EP4313125A1 (enExample)
JP (1) JP2024513781A (enExample)
KR (1) KR20230165259A (enExample)
CN (1) CN117120080A (enExample)
AU (1) AU2022251011A1 (enExample)
CA (1) CA3213222A1 (enExample)
GB (1) GB202104715D0 (enExample)
IL (1) IL306136A (enExample)
WO (1) WO2022207925A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202104715D0 (en) * 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202202880D0 (en) 2022-03-02 2022-04-13 Achilles Therapeutics Uk Ltd Methods for peptide synthesis
GB202205147D0 (en) 2022-04-07 2022-05-25 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
EP4681208A1 (en) 2023-03-17 2026-01-21 T-Cypher Bio Ltd Prediction of immunogenicity
GB202307096D0 (en) 2023-05-12 2023-06-28 Achilles Therapeutics Uk Ltd Method
WO2024256485A1 (en) 2023-06-15 2024-12-19 Achilles Therapeutics Uk Limited Identification of neoantigen peptides
GB202407727D0 (en) 2024-05-31 2024-07-17 Ucl Business Ltd Reporters constructs, systems and assays

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882867A1 (en) 2012-08-10 2015-06-17 The Broad Institute, Inc. Methods and apparatus for analyzing and quantifying dna alterations in cancer
BR112015025460B1 (pt) * 2013-04-07 2024-01-02 The Broad Institute, Inc. Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
US11725237B2 (en) * 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP6740127B2 (ja) 2013-12-06 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物ワクチン用製剤
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
ES2836273T3 (es) * 2015-04-27 2021-06-24 Cancer Research Tech Ltd Método para el tratamiento del cáncer
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
JP6904953B2 (ja) * 2015-12-03 2021-07-21 アレス トレーディング ソシエテ アノニム 細胞クローン性を決定する方法
CA3050109A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
WO2018170578A1 (en) * 2017-03-20 2018-09-27 Ontario Institute For Cancer Research (Oicr) Cancer risk based on tumour clonality
EP3651791A1 (en) * 2017-07-14 2020-05-20 The Francis Crick Institute Limited Analysis of hla alleles in tumours and the uses thereof
EP3622522A1 (en) * 2017-12-01 2020-03-18 Illumina, Inc. Methods and systems for determining somatic mutation clonality
IL259392A (en) * 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neoantigens
US11189361B2 (en) * 2018-06-28 2021-11-30 International Business Machines Corporation Functional analysis of time-series phylogenetic tumor evolution tree
CN111785322A (zh) * 2019-12-30 2020-10-16 杭州慕谷基因科技有限公司 一种结肠腺癌基因组变异与肿瘤进化关系的研究方法
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202205147D0 (en) * 2022-04-07 2022-05-25 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof

Similar Documents

Publication Publication Date Title
Roberts et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival
JP7155470B2 (ja) 免疫原性がん特異的エピトープのためのランク付けシステム
CN113228190B (zh) 分类和/或鉴定癌症亚型的系统和方法
Jonsson et al. Mutations in collagen, type XVII, alpha 1 (COL17A1) cause epithelial recurrent erosion dystrophy (ERED)
JP2019145114A (ja) 高解像度での対立遺伝子の同定
JP2015533473A (ja) 個別のがんワクチン及び適応免疫細胞療法
US10711311B2 (en) Genomic rearrangements associated with prostate cancer and methods of using the same
KR20190038935A (ko) 면역요법 마커들 및 그 용도들(immunotherapy markers and uses therefor)
Sammut et al. Predictability of B cell clonal persistence and immunosurveillance in breast cancer
Young et al. Innate immune gene expression in Acropora palmata is consistent despite variance in yearly disease events
JP2024513781A (ja) クローナルなネオ抗原の同定及びその使用
Pinto et al. Functional annotation of proteome encoded by human chromosome 22
CA3236814A1 (en) Systems and methods for gene expression and tissue of origin inference from cell-free dna
WO2021231614A1 (en) System and method for gene expression and tissue of origin inference from cell-free dna
Hasan et al. Copy number architectures define treatment-mediated selection of lethal prostate cancer clones
US20170072071A1 (en) Inflammation-enabling polypeptides and uses thereof
JP2017514505A (ja) 急性骨髄性白血病の新規バイオマーカー
Yamahira et al. Ghost introgression in ricefishes of the genus Adrianichthys in an ancient Wallacean lake
CN115925869B (zh) Axin2突变体及其应用
CN112424382A (zh) Hla多样性的定量评分
Ernst Computational methods for improved cancer risk prediction based on multi-gene panel analysis in a routine diagnostic setting
CN116083485B (zh) 一种靶向载体、ATTRm疾病模型的构建方法及其应用
Skelly et al. Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response in mice and humans
Manyisa Whole exome sequencing to investigate genetic variants of non-syndromic hearing impairment in a population of African ancestry
JP2024533501A (ja) 患者の腫瘍の個別化された新生抗原を生成する方法